Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 480 | 52 | 428 |
| Samples | 132 | 25 | 107 |
| Peptides | 102 | 20 | 88 |
Function
TNNI2 · Troponin I2, fast skeletal type
This gene encodes a fast-twitch skeletal muscle protein, a member of the troponin I gene family, and a component of the troponin complex including troponin T, troponin C and troponin I subunits. The troponin complex, along with tropomyosin, is responsible for the calcium-dependent regulation of striated muscle contraction. Mouse studies show that this component is also present in vascular smooth muscle and may play a role in regulation of smooth muscle function. In addition to muscle tissues, this protein is found in corneal epithelium, cartilage where it is an inhibitor of angiogenesis to inhibit tumor growth and metastasis, and mammary gland where it functions as a co-activator of estrogen receptor-related receptor alpha. This protein also suppresses tumor growth in human ovarian carcinoma. Mutations in this gene cause myopathy and distal arthrogryposis type 2B. Alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Mar 2009].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 95 amino-acid changes on canonical ENST00000381911 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in TNNI2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in TNNI2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Endometrial Carcinoma | 4/42 10% | 7/612 1% |
| Melanoma | 1/210 0% | 18/1899 1% |
| Other Sarcomas | 2/69 3% | 3/699 0% |
| Non-Small Cell Lung Carcinoma | 2/304 1% | 9/1390 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 5/810 1% |
| Gastric Carcinoma | 1/74 1% | 10/1809 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 8/1592 0% |
| Colorectal Carcinoma | 4/143 3% | 11/3239 0% |
| Cervical Carcinoma | 0/35 0% | 2/422 0% |
| Mesothelioma | 1/62 2% | 0/165 0% |
| Neuroendocrine Tumour | 2/154 1% | 1/577 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 3/752 0% |
| Ovarian Carcinoma | 2/109 2% | 2/998 0% |
| Other Solid Cancers | 0/94 0% | 5/1515 0% |
| Bladder Carcinoma | 0/58 0% | 2/956 0% |
| Hepatocellular Carcinoma | 0/46 0% | 4/2210 0% |
| Head and Neck Carcinoma | 0/85 0% | 3/1574 0% |
| Breast Carcinoma | 3/144 2% | 2/3264 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 4/2550 0% |
| Neuroblastoma | 2/87 2% | 0/1331 0% |
| Esophageal Carcinoma | 0/23 0% | 1/769 0% |
| B-Cell Non-Hodgkins Lymphoma | 1/88 1% | 2/2534 0% |
| Non-Cancerous | 0/104 0% | 1/830 0% |
| Biliary Tract Carcinoma | 0/54 0% | 1/950 0% |
| Kidney Carcinoma | 0/85 0% | 1/1862 0% |
| Glioma | 0/52 0% | 1/2127 0% |
| Prostate Carcinoma | 0/13 0% | 1/2105 0% |
Mutation Distribution
Where TNNI2 is mutated · all tissues, split by cell line vs tissue
How many mutations in TNNI2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 480 mutations in TNNI2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|